[Management of bladder cancer in unfit patients].

Service Urologie, Hôpital Saint Louis 1, avenue Claude-Vellefaux, Paris cedex 10, France.
Progrès en Urologie (Impact Factor: 0.77). 03/2010; 20 Suppl 1:S54-6.
Source: PubMed

ABSTRACT Adjuvant therapies in bladder cancer are based on risk of recurrence and associated comorbidities (renal failure). Lymph node involvement is the most important prognostic factor for decision. Two adjuvant chemotherapies exist: MVAC or GC. In unfit patients, association (Gemcitabine and Taxanes) could be proposed. Indication of adjuvant radiotherapy depends on metastatic risk and resection margins. Concomitant chemotherapy and radiotherapy should be proposed to selected patients who refuse or are not candidate for radical cystectomy.